Brief Article
Copyright ©2012 Baishideng Publishing Group Co.
World J Gastroenterol. Nov 21, 2012; 18(43): 6277-6283
Published online Nov 21, 2012. doi: 10.3748/wjg.v18.i43.6277
Table 3 Clinical characteristics in virological recurrence and non-recurrence
Virological recurrence(n = 20)Virological non-recurrence(n = 28)P value
Age, yr (mean ± SD)46.7 ± 12.138.8 ± 12.70.022
Sex (male/female)11/929/190.561
Pretreatment ALT level (IU/L)199 (40-374)189 (11-364)0.491
Pretreatment HBV DNA level (log10 copies/mL)7.7 (5.1-10)7 (5.0-9.1)0.125
Time to undetectable HBV (mo)6.7 (2.3-39.4)9.1 (1.3-25.0)0.490
Time to HBeAg seroconversion (mo)13.9 (0.8-39.4)12.7 (1.4-31.2)0.744
Consolidation treatment duration (mo)10.3 (6-23.9)11.7 (6-37.9)0.517
Total treatment duration (mo)25.6 (9.6-47.4)27.0 (9.4-43.3)0.358
Antiviral agent (entecavir/clevudine)15/516/120.236